VOLTAREN ARTHRITIS PAIN (diclofenac sodium) by GSK is (ak) is unknown. First approved in 2007.
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
VOLTAREN ARTHRITIS PAIN is a topical gel formulation of diclofenac sodium approved in 2007 for localized arthritis pain relief. The mechanism of action is classified as unknown in regulatory records, though diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that typically works by inhibiting prostaglandin synthesis. This product represents GSK's topical NSAID offering in the OTC and Rx arthritis pain market.
Product is in late-stage lifecycle with moderate competitive pressure (30%), signaling potential team consolidation and transition focus toward line extensions or new launches.
(AK) is unknown.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Efficacy of Diclofenac Sodium Shock Wave Phonophoresis on Patients With Subacromial Impingement Syndrome
A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp
To Evaluate the Superiority of Fixed Combination (Orfenadrine 35mg, Acetaminophen 325mg, Caffeine 65mg and Diclofenac Sodium 50mg) Compared to Voltaren® (Diclofenac Sodium 50mg) in the Treatment of Acute Postural Low Back Pain.
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp
Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp
Worked on VOLTAREN ARTHRITIS PAIN at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on VOLTAREN ARTHRITIS PAIN in 2024 means supporting a legacy product in defensive mode with limited headroom for growth. Career progression typically involves protecting market share, managing generic competition, and executing efficiency initiatives rather than leading innovation or market expansion.